drugset / Trial / NCT07293351
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with other agents in participants with advanced Renal Cell Carcinoma (RCC)
Timeline
- Start
- 2026-03-26
- Primary completion
- 2029-11-28
- Completion
- 2031-11-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | — | — |
| Subject | Casdatifan | Small molecule | — | — |
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | Pumitamig | Protein / enzyme biologic | — | — |